BioLife Solutions Q1 revenue rises, beats estimates

BioLife Solutions

07/05/2026 21:14

Overview

US cell processing tools supplier's Q1 revenue rose 25% yr/yr, beating analyst expectations

Adjusted EBITDA for Q1 was $6.2 mln, up from $5.4 mln a year ago

Company reiterated 2026 revenue guidance of $112.5 mln to $115 mln, up 17-20% yr/yr

Outlook

BioLife Solutions reiterates 2026 revenue guidance of $112.5 mln to $115.0 mln

Company expects 2026 gross margin in the mid-60% range

BioLife Solutions anticipates expansion of adjusted EBITDA margin for 2026

Result Drivers

BIOPRESERVATION MEDIA DEMAND - Co said healthy demand for its biopreservation media and growth across its broader product portfolio drove Q1 results, per CEO Roderick de Greef

CGT MARKET MOMENTUM - Co said continued momentum in the cell and gene therapy market, including expansion into larger indications and renewed funding activity, contributed to results

Company press release: ID:nPnDRPtpa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$27.50 mln
$25.66 mln (10 Analysts)
Q1 EPS
$0.02
Q1 Adjusted Gross Margin
64.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for BioLife Solutions Inc is $32.50, about 49.4% above its May 6 closing price of $21.75

The stock recently traded at 89 times the next 12-month earnings vs. a P/E of 242 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)